Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Annals of Clinical Microbiology and Antimicrobials

Fig. 6

From: Potential factors contributing to the poor antimicrobial efficacy of SAAP-148 in a rat wound infection model

Fig. 6

In vitro killing assay of SAAP-148 against MRSA in PBS, plasma, eschar or skin extract. Approximately 105 CFU/mL MRSA that was suspended in PBS or in PBS with 50% (v/v) plasma, or 50% (v/v) eschar extract, or 50% (v/v) skin extract, was exposed to 10 µL of increasing dosages (0–30 nmol) of SAAP-148 in PBS. Results are expressed as the LR versus the amount of SAAP-148 in nmol. Each value represents the mean ± SD of three independent experiments performed in duplicate

Back to article page